{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chlamydia-uncomplicated-genital/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"07eef3f6-7862-5fc9-b60f-ffa9d201996a","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field 078c5041-c82f-4119-8b57-01e9c2e2badf --><h2>Erythromycin</h2><!-- end field 078c5041-c82f-4119-8b57-01e9c2e2badf -->","summary":"","htmlStringContent":"<!-- begin item a2700af8-a97c-402a-aae0-49abe6d7e43f --><!-- end item a2700af8-a97c-402a-aae0-49abe6d7e43f -->","topic":{"id":"9fd72b23-86c9-5ce5-bbdd-598398d0e8ea","topicId":"7ce33f6f-747f-41e5-b18b-09b2071a7d93","topicName":"Chlamydia - uncomplicated genital","slug":"chlamydia-uncomplicated-genital","lastRevised":"Last revised in January 2021","chapters":[{"id":"0b0636d2-117b-5108-b70c-d19a794db377","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dda664e4-4864-5386-8bf2-ae38fe324071","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6af905a1-8c41-53d9-b5ca-e96a0b2548be","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84014645-1e22-51ca-b89b-52cd820d41b7","slug":"changes","fullItemName":"Changes"},{"id":"66fb5a16-c4f5-562e-9a73-84371e2bbe0d","slug":"update","fullItemName":"Update"}]},{"id":"82517c94-8e8a-5c62-b7d6-670ad4404258","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0f150da5-1397-5e5d-b3dd-c9f2716423aa","slug":"goals","fullItemName":"Goals"},{"id":"f52e0aef-b3ad-5e13-b9ed-d426b4fa2f77","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ba38cbe0-ef08-5c56-a1f4-9a962b32ad9f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ced83fa-49d9-5243-8a7f-d942baa4bc1f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"5887995c-3455-537d-98cc-b1aeb54144ed","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0f2bffb-9529-57db-a995-191cba2d4e9f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"824044f0-a305-5a18-9a1d-bf36875a6ce8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5b8da5a2-6086-58db-9ad4-94fe2eb8bd48","slug":"definition","fullItemName":"Definition"},{"id":"ae31b546-618f-5b61-bf90-254c4868b504","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8cd27f8c-d2f1-57ac-83e8-ed035b78ee51","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"ab8dc958-d4dc-5fef-ac7c-bc2b5865fdbe","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"3a69be68-2fd6-509b-85f4-164afc701ba8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a927a8de-387f-5d99-8924-b8836a37e1a0","slug":"screening-for-chlamydia-in-asymptomatic-men-women","fullItemName":"Screening for chlamydia in asymptomatic men and women"},{"id":"9da777e0-887a-5bb6-af7a-f6f0b986dbf4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"0a0b5d7a-0455-5688-90d5-253f427816b6","slug":"testing-to-confirm-the-diagnosis","fullItemName":"Testing to confirm the diagnosis"}]},{"id":"366e3be0-ac7e-5c90-baed-b3485d6e47ae","fullItemName":"Management","slug":"management","subChapters":[{"id":"9b3c090d-c63e-54c5-8cd1-1f401bc12c7b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0cd2f484-1947-55ec-980e-1d0293ab355e","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"48da76f5-5041-504f-ab81-69b4fe7ff549","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"f100927d-5a5a-5112-bec9-59e5e4d4f040","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07eef3f6-7862-5fc9-b60f-ffa9d201996a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"dacb6886-00ac-5160-9ee9-3ec19959d6ee","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"41a663fd-74e7-5b4b-b936-d4894268ff1f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"34dd7d77-0b55-5661-b769-73e6cade3309","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ffbef724-e30a-592a-836b-c4c5163d2e15","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0964fb39-dd03-54bb-af48-c376a46d685b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d69f8f7d-515f-5861-85b0-f5d6cf0ecfac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2c32cb59-e5a3-5af2-b976-e11d73a2ea8a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87f9e401-f03f-547f-a524-e2f66bfb58c0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69fd8a3f-633f-5092-85dd-f2220728872d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"64aa788a-84b3-5805-8189-987757de9eb2","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field f4b67146-76f7-4e34-89af-668bd260d125 --><h3>What contraindications and cautions are important with erythromycin?</h3><!-- end field f4b67146-76f7-4e34-89af-668bd260d125 -->","summary":"","htmlStringContent":"<!-- begin item af5bd64b-f09e-4dc2-865c-adc15fd250dc --><!-- begin field 2967d002-54ae-4bdb-ad56-0883e022fb61 --><p><strong>Do not prescribe erythromycin to people with:</strong></p><ul><li>Porphyria.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval</li></ul><p><strong>Prescribe erythromycin with caution to people with:</strong></p><ul><li>Hepatic impairment (or people concomitantly receiving potentially hepatotoxic drugs) — erythromycin is mainly excreted by the liver.</li><li>Moderate to severe renal impairment:<ul><li>Give a maximum dose for erythromycin of 1.5 g a day in severe renal impairment due to the risk of ototoxicity.</li></ul></li><li>Myasthenia gravis — macrolides may aggravate weakness symptoms.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BNF 71, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">MHRA, 2020</a>]</p><!-- end field 2967d002-54ae-4bdb-ad56-0883e022fb61 --><!-- end item af5bd64b-f09e-4dc2-865c-adc15fd250dc -->","subChapters":[]},{"id":"84ffaccd-7134-58ce-928e-378e255705be","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a5929833-2575-4b90-9587-7ddcd143bfe2 --><h3>What are the adverse effects of erythromycin?</h3><!-- end field a5929833-2575-4b90-9587-7ddcd143bfe2 -->","summary":"","htmlStringContent":"<!-- begin item 23867615-05a1-4c09-a2a7-7036c843f689 --><!-- begin field 0066916f-6b95-464e-b1ca-234a23b2eef8 --><ul><li><strong>Nausea, vomiting, abdominal discomfort, and diarrhoea</strong> are the most common adverse effects of macrolides.</li><li><strong>Consider pseudomembranous colitis</strong> if a person develops severe diarrhoea during or after treatment with erythromycin.<ul><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis</strong> is rarely associated with erythromycin.</li><li><strong>Hepatotoxicity (including cholestatic jaundice) and rash</strong> have infrequently been reported following treatment with erythromycin.</li><li><strong>Other adverse effects reported rarely or very rarely include</strong> pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BNF 71, 2016</a>]</p><!-- end field 0066916f-6b95-464e-b1ca-234a23b2eef8 --><!-- end item 23867615-05a1-4c09-a2a7-7036c843f689 -->","subChapters":[]},{"id":"b8016a85-9759-58e2-8636-ea62d9f0dcf8","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 068ede2d-399a-4964-a017-efc59f20d849 --><h3>What drug interactions are important with erythromycin?</h3><!-- end field 068ede2d-399a-4964-a017-efc59f20d849 -->","summary":"","htmlStringContent":"<!-- begin item d45acd69-6ffb-4568-a39c-545dbedb0fb0 --><!-- begin field 7fe02600-5d07-4d4c-971d-05f7cc10c2bd --><ul><li><strong>Theophylline </strong>— erythromycin increases plasma concentrations of theophylline, and theophylline may also reduce absorption of oral erythromycin.<ul><li>Check theophylline levels 48 hours after starting erythromycin, and adjust the dose of theophylline accordingly.</li></ul></li><li><strong>Carbamazepine </strong>— erythromycin inhibits the cytochrome P450 enzyme CYP3A4, resulting in reduced carbamazepine metabolism.<ul><li>Advise the person to report symptoms of carbamazepine toxicity (such as dizziness, diplopia, ataxia, or confusion).</li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin </strong>— occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if erythromycin is taken with atorvastatin or simvastatin.<ul><li>For simvastatin — do not prescribe erythromycin to a person taking simvastatin, as simvastatin is extensively metabolized by CYP3A4. If treatment with erythromycin cannot be avoided, stop treatment with simvastatin during the course of treatment.</li><li>For atorvastatin — avoid concurrent use with erythromycin, as atorvastatin is moderately metabolized by CYP3A4. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Other statins — clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. Fluvastatin is not dependent on CYP3A metabolism; therefore, interaction with erythromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Drugs that prolong the QT interval</strong> (such as haloperidol, sotalol, and amisulpride) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Use a suitable alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-<sub>2</sub> agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Use a suitable alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li><li><strong>Calcium-channel blockers (CCBs) </strong>— due to an increased risk of hypotension, caution is advised with the concurrent use of macrolides and CCBs metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BNF 71, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">MHRA, 2020</a>]</p><!-- end field 7fe02600-5d07-4d4c-971d-05f7cc10c2bd --><!-- end item d45acd69-6ffb-4568-a39c-545dbedb0fb0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}